$FTLF

Engaging In Insider Activity, Jakob York At FitLife Brands Exercises Options Worth $0 - FitLife Brands (NASDAQ:FTLF)

A substantial insider activity was disclosed on September 8, as York, Chief Financial Officer at FitLife Brands FTLF, reported the exercise of a large sell of company stock options. What Happened: In an insider options sale disclosed in a Form 4 filing on Monday with the U.S.

Original reporting
Benzinga · Benzinga Insights
Published Sep 8, 2025, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 8, 2025, 3:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Engaging In Insider Activity, Jakob York At FitLife Brands Exercises Options Worth $0 - FitLife Brands (NASDAQ:FTLF) — source image
Decision brief

The 30-second read

$FTLFNeutralLow
01

Why it matters

Given the non-material nature of the transaction, the impact on market perception is limited.

02

Market read

The activity has minimal relevance to the broader market or sector, primarily of interest to company-specific stakeholders.

03

What to watch

Potential upcoming material events or disclosures not captured here could influence the stock; monitor for future insider filings or company news.

Timing: low

Background

The insider activity involves the CFO of FitLife Brands exercising stock options, which is a routine corporate action.

Company-level read

Ticker impact

$FTLFNeutralMedium confidence
Context

The insider activity involves the CFO exercising stock options, which is a significant insider transaction. However, the reported exercise value is $0, indicating no immediate cash inflow or outflow, and possibly a non-material transaction from a financial perspective.

Expected impact

Minimal to no immediate impact on stock price; potential for slight positive sentiment if viewed as confidence in the company, but unlikely to cause significant price movement.

Evidence & confidence

The exercise of options without a monetary gain or loss suggests no strong insider conviction or signaling. The low relevance score and the absence of material financial change imply limited impact.

$FTLFNeutralMedium confidence
Context

Same as above, the activity is specific to the company's CFO and involves non-material options exercise, which has minimal influence on market perception or stock price.

Expected impact

No significant price movement expected.

Evidence & confidence

Insider exercises with no monetary impact are generally viewed as routine and do not serve as strong buy or sell signals.

Market effects

Limited; the activity does not indicate sector-wide trends.

Minimal; the insider activity is company-specific.

Negligible; no broader market implications.

Counterpoint

Some investors might interpret insider exercising options as a sign of confidence, but in this case, the lack of monetary gain suggests caution.

Key entities

  • Jakob York

    Chief Financial Officer of FitLife Brands

  • FitLife Brands

    A company listed on NASDAQ with ticker FTLF.

Related articles

$FTLFMed

FitLife Brands (FTLF) Q2 2026 Earnings Call Transcript

FitLife Brands (FTLF) reported Q2 2026 earnings. Legacy FitLife's gross margin rose to 41.7%, but contribution fell 25.9% to $4.2M. Irwin's revenue hit $14.1M, with Amazon sales growing. The company is improving supply chain, product development, and marketing. SG&A costs dropped 3.8% sequentially. The term loan balance is $36.1M, with $8.6M of debt paid since the Irwin acquisition.

$FTLFMed

FitLife Brands Q2 Earnings Call Highlights

FitLife Brands (NASDAQ:FTLF) reported Q2 call highlights. Irwin direct Amazon sales rose from about $500k monthly in Dec 2025 to about $1m in June 2026, with July comparable to June. Legacy revenue fell 23% YoY to $12.4m; gross margin 41.7%. FitLife is extending Irwin shelf life and launching new products. It paid about $1.5m term-loan, cutting term-loan to $36.1m.

$FTLFMed

FITLIFE BRANDS, INC. (FTLF): Results of Operations and Financial Condition

FITLIFE BRANDS, INC. (FTLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FitLife Brands Announces Second Quarter 2026 Results OMAHA, NE – August 13, 2026 – FitLife Brands, Inc. (“ FitLife ” or the “ Company ”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.